APA (7th ed.) Citation

Qingli Cui, Yanhui Hu, Qingan Cui, Daoyuan Wu, Yuefeng Mao, Dongyang Ma, & Huaimin Liu. (2022). Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Qingli Cui, Yanhui Hu, Qingan Cui, Daoyuan Wu, Yuefeng Mao, Dongyang Ma, and Huaimin Liu. Osimertinib Rechallenge With Bevacizumab Vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Qingli Cui, et al. Osimertinib Rechallenge With Bevacizumab Vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance. Frontiers Media S.A., 2022.